Sanofi deepens its Owkin bet with a five-year deal to build bespoke drug-development agents
A 3D rendering of a biological cell from the company’s homepage, where it animates to reveal layers of…
Tempus Unveils the Next-Generation of Lens, Expanding its Agentic AI Platform for Oncology Drug Development
CHICAGO, May 31, 2026–(BUSINESS WIRE)–Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to…
Gilead (GILD), Tempus AI (TEM) Expand Multi-Year Oncology R&D Collaboration
Gilead Sciences Inc. (NASDAQ:GILD) is one of the 8 Best Quality Stocks to Buy According to Hedge Funds.…